A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by stimulating the mother’s body’s defences to produce defence proteins, which are then passed to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The new study shows that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85% protection when immunised 4 weeks before birth
- Antibodies from the mother passed through placenta protect newborns from day one
- Protection achievable with two-week gap before early delivery
- Vaccination during third trimester still provides significant infant protection
Compelling evidence from recent research
The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a comprehensive study carried out throughout England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month timeframe, providing robust and representative data of the vaccine’s practical effectiveness. The study’s findings have been endorsed by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scale of this research provides healthcare professionals and prospective parents with confidence in the vaccine’s established performance across diverse populations and circumstances.
The results present a notable picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This marked difference underscores the vaccine’s vital importance in reducing the risk of serious illness in newborns. The drop in hospital admissions above 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Study methodology and scope
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The large sample size and thorough nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology captured actual clinical results rather than experimental conditions, providing real-world data of how the vaccine works when administered across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the threats
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection triggers inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to feed and breathe properly. Parents commonly see their babies fighting for breath, their chests heaving as they work to get sufficient oxygen into their compromised lungs. Whilst most newborns improve through supportive care, a small but significant number die from RSV-related complications each year, making prevention through vaccination a critical public health objective for safeguarding the youngest and most at-risk people in our communities.
- RSV produces lung inflammation, resulting in serious respiratory problems in infants
- Approximately half of newborns acquire the virus in their first few months of life
- Symptoms range from mild colds to life-threatening chest infections needing hospital treatment
- More than 20,000 UK babies require serious hospital care for RSV each year
- Few infants die from RSV complications each year in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have emphasised the value of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts recommend women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies through the placenta.
The messaging from health authorities stays clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach recognises the realities of pregnancy and childbirth whilst ensuring strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Certain regions have attained greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and availability of the jab. These regional differences reflect variations in healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts rolling out varied communication campaigns to engage with expectant mothers
- Geographic variations in vaccination coverage levels across England necessitate strategic intervention
- Community health services tailoring initiatives to suit local requirements and situations
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness translates into real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the rollout of this preventative solution, the 80% decrease in admissions means thousands of infants shielded from severe infection. Parents no longer face the troubling prospect of seeing their babies struggle for breath or difficulty feeding, symptoms that characterise severe RSV infections. The vaccine has substantially transformed the terrain of neonatal respiratory health, giving expectant mothers a preventative option to safeguard their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection led to severe brain damage, the vaccine’s availability carries significant emotional significance. His mother’s support of the jab emphasises the life-altering consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has offered substantial reassurance to women in pregnancy during their final trimester, converting what was once an inevitable seasonal threat into a manageable health risk.